Our platform technology creates unprecedented opportunities to address previously intractable therapeutic challenges
In Conversation
Drug assets are not like wine, they need to be in the right hands to realise their full potential.
Our vision is clear...In ophthalmology, you cannot rely on just one or two products. You must serve the entire field.
This journey has reminded me that leadership is not defined by institutional scale, but by resilience, clarity of purpose, and the ability to deliver.
As long as we stay anchored in innovation and aligned with patient needs, we are confident in our ability to grow, differentiate, and endure.
For physicians and patients, these approvals are vital: after roughly two decades without a single approved Alzheimer’s treatment, having options restores hope and underscores the importance…
Our goal is to develop genome editing therapies that are both highly potent and fundamentally safe.
Our transition from public health to precision-targeted therapeutics reflects both the maturity of our platform and the ambition behind it.
To establish Hong Kong as a serious global contender in biotechnology, it is not enough to allocate funding alone. What is required is the cultivation of…
"Our ambition is led by our ability to connect science, compliance, and commercial readiness across borders."
We aim to ensure that scientific discoveries translate into real-world innovations that benefit patients and society.
With the right expertise and collaborative spirit, there is no reason why Hong Kong should not be a leader in advanced cell therapies.
